Drugs / GS-9411
GS-9411
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01025713 | Dec 2009 → Mar 2010 | cystic fibrosis, mucus inspissation of respiratory tract | Gilead Sciences | Withdrawn | No outcome recorded |
| Phase 1 | NCT00999531 | Oct 2009 → Feb 2010 | cystic fibrosis, mucus inspissation of respiratory tract | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT00951522 | Sep 2009 | cystic fibrosis | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT00800579 | Nov 2008 → Feb 2009 | cystic fibrosis | Gilead Sciences | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00274313 | Jan → Aug 2006 | cystic fibrosis | Parion Sciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00852839 | Feb → Oct 2009 | Sjogren syndrome | Parion Sciences | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-9411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00800579 ↗ |
| Known as | 552-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00852839 ↗ |
| Known as | PS-552-02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL212432 ↗ |
| Action | Inhibit | “sodium-channel blocker” NCT00274313 ↗ |
| Modality | Small molecule | — CHEMBL212432 ↗ |
| Route | Inhaled | “552-02 will be inhaled once a day for 14 days using a nebulizer.” NCT00274313 ↗ |